Interferon Alpha-2b in the Pathological Complete Response Advanced Epithelial Ovarian Cancer

Abstract

Objective To evaluate the efficacy of the interferon alpha-2b for prophylaxis of recurrence in advanced epithelial ovarian cancer.

Main outcome measure Recurrence rate, duration of recurrence, survival, and drug toxicities.

Results The evaluable patients included 20 cases of the advanced epithelial cancer, achieved PCR after postoperative chemotherapy. Interferon alpha-2b was administrated 5 million units subcutaneously, 3 times a week for 6 months. The recurrence occurred 6 out of 20 cases (30.0%) (95% CI 0.099, 0.501). The histopathology and chemotherapeutic regimen showed no significant relationship with the recurrence. Almost of patients had fever grade 1-2 in 1-3 weeks of treatment. The haematologic toxicity was found, haemoglobin level grade 3 of 15.0% and thrombocytopenia grade 2 of 5.0%